Design and optimization of renin inhibitors: Orally bioavailable alkyl amines

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 13, 2009, Pages 3541-3545

  Tice, Colin M ^a   Xu, Zhenrong ^a   Yuan, Jing ^a   Simpson, Robert D ^a   Cacatian, Salvacion T ^a   Flaherty, Patrick T ^a   Zhao, Wei ^a   Guo, Joan ^a   Ishchenko, Alexey ^a   Singh, Suresh B ^a   Wu, Zhongren ^a   Scott, Boyd B ^a   Bukhtiyarov, Yuri ^a   Berbaum, Jennifer ^a   Mason, Jennifer ^a   Panemangalore, Reshma ^a   Cappiello, Maria Grazia ^a   Müller, Dominik ^b   Harrison, Richard K ^a   McGeehan, Gerard M ^a   Dillard, Lawrence W ^a   Baldwin, John J ^a   Claremon, David A ^a   more..

^a Vitae Pharmaceuticals   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Antihypertensive; Aspartyl protease; Renin; Structure based drug design

Indexed keywords

ALIPHATIC AMINE; ALISKIREN; RENIN; RENIN INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG HALF LIFE; DRUG SYNTHESIS; ENZYME INHIBITION; HYPERTENSION; IC 50; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSGENIC RAT;

ADMINISTRATION, ORAL; AMINO ACID SEQUENCE; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HUMANS; METHYLAMINES; RATS; RATS, TRANSGENIC; RENIN; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS;

EID: 66349100410     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.04.140     Document Type: Article

References (17)

1. Zaman M.A., Oparil S., and Calhoun D.A. Nat. Rev. Drug Discovery 1 (2002) 621
2. Scott B.B., McGeehan G., and Harrison R.K. Curr. Protein Peptide Sci. 7 (2006) 241
3. Naseem R.H., Hedegard W., Henry T.D., Lessard J., Sutter K., and Katz S.A. Basic Res. Cardiol 100 (2005) 139
4. Greenlee W.J. Med. Res. Rev. 10 (1990) 173
5. Rosenburg S.H. Prog. Med. Chem. 32 (1995) 37
6. Clozel J.P., and Fischli W. Hypertension 22 (1993) 9
7. Tice C.M. Ann. Reports Med. Chem. (2006) 155
8. Rahuel J., Rasetti V., Maibaum J., Rueger H., Goschke R., Cohen N.C., Stutz S., Cumin F., Fuhrer W., Wood J.M., and Grutter M.G. Chem. Biol. 7 (2000) 493
9. Marki H.P., Binggeli A., Bittner B., Bohner-Lang V., Breu V., Bur D., Coassolo P., Clozel J.P., D'Arcy A., Doebeli H., Fischli W., Funk C., Foricher J., Giller T., Gruninger F., Guenzi A., Guller T., Hartung R., Hirth G., Jenny C., Kansy M., Klinkhammer U., Lave T., Lohri B., Luft F.C., Mervaala E.M., Muller D.N., Muller M., Montavon F., Oefner C., Qiu C., Reichel A., Sanwald-Ducray P., Scalone M., Schleimer M., Schmid R., Stadler H., Treiber A., Valdenaire O., Vieira E., Waldmeier P., Wiegand-Chou R., Wilhelm M., Wostl W., Zell M., and Zell R. Il Farmaco 56 (2001) 21
10. Powell N.A., Ciske F.L., Cai C., Holsworth D.D., Mennen K., Van Huis C.A., Jalaie M., Day J., Mastronardi M., McConnell P., Mochalkin I., Zhang E., Ryan M.J., Bryant J., Collard W., Ferreira S., Gu C., Collins R., and Edmunds J.J. Bioorg. Med. Chem. 15 (2007) 5912
11. Corey E.J., Bakshi R.K., Shibata S., Chen C.P., and Singh V.K. J. Am. Chem. Soc. 109 (1987) 7925
12. Rosowsky A., and Wright J.E. J. Org. Chem. 48 (1983) 1539
13. 50 is defined as the concentration of a particular inhibitor that reduces the formation of product by 50% relative to a control sample containing no inhibitor. (Wang G. T. et al. Anal. Biochem. 1993, 210, 351; Nakamura, N. et al. J. Biochem. (Tokyo) 1991, 109, 741; Murakami, K. et al. Anal Biochem. 1981, 110, 232).
14. 50 is defined as the concentration of a particular inhibitor that reduces the formation of product by 50% relative to a control sample containing no inhibitor.
15. The oral bioavailability of aliskiren (2) in rat, determined by bioassay, has been reported to be 2.4%:. Wood J.M., Schnell C.R., Cumin F., Menard J., and Webb R.L. J. Hypertens 23 (2005) 417
16. Luft F.C., Mervaala E., Muller D.N., Gross V., Schmidt F., Park J.K., Schmitz C., Lippoldt A., Breu V., Dechend R., Dragun D., Schneider W., Ganten D., and Haller H. Hypertension 33 (1999) 212
17. Mervaala E., Muller D.N., Schmidt F., Park J.-K., Gross V., Bader M., Breu V., Ganten D., Haller H., and Luft F.C. Hypertension 35 (2000) 587